On December 24, Gelonghui reported that Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that its subsidiary, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., has received the "Approval Notification for Clinical Trial of Maltofer Iron Capsules" issued by the State Drug Administration, and the company will conduct clinical trials in the near future.
Maltofer Iron Capsules are suitable for the treatment of iron deficiency anemia in adults. Maltofer Iron is a complex containing iron ions, which is different from iron salt compounds; it dissociates when absorbed by the gastrointestinal tract, allowing iron ions and maltofer to be absorbed separately. Iron ions are taken up by intestinal wall cells and transferred to transferrin and ferritin, thereby increasing the concentration of iron ions in serum, including transferrin and ferritin saturation, achieving the effect of iron supplementation. Unlike traditional oral iron supplements based on iron salts, Maltofer Iron can effectively reduce patients' intolerance to iron supplements. According to inquiries, there are currently no similar products approved for sale in the domestic market.